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Increased plasma levels of asymmetric dimethylarginine
(ADMA) are associated with endothelial dysfunction and
predict the progression to dialysis and death in patients
with chronic kidney disease. The effects of these increased
ADMA levels in renal transplant recipients, however, are
unknown. We used the data from ALERT, a randomized,
double-blind, placebo-controlled study of the effect of
fluvastatin on cardiovascular and renal outcomes in 2102
renal transplant recipients with stable graft function on
enrollment. Patients who were initially randomized to
fluvastatin or placebo in the 5- to 6-year trial were offered
open-label fluvastatin in a 2-year extension of the original
study. After adjustment for baseline values for established
factors in this post hoc analysis, ADMA was found to be
a significant risk factor for graft failure or doubling of
serum creatinine (hazard ratio 2.78), major cardiac events
(hazard ratio 2.61), cerebrovascular events (hazard ratio 6.63),
and all-cause mortality (hazard ratio 4.87). In this trial
extension, the number of end points increased with
increasing quartiles of plasma ADMA levels. All end points
were significantly increased in the fourth compared to the
first quartile. Our study shows that elevated plasma levels
of ADMA are associated with increased morbidity, mortality,
and the deterioration of graft function in renal transplant
recipients.
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Patient and graft survival after renal transplantation has
improved considerably over the recent decades. Current
5- and 10-year patient survival rates are around 85 and
66%, and allograft half-lives have improved from 7.7 years
in the mid 1980s to 10.9 years in mid 1990s.1 However, life
expectancy of renal transplant recipients is still shortened
and premature graft failure is a major clinical problem.
We have previously shown that atherogenic lipids are risk
factors for premature cardiac events in renal transplant
recipients, and that this risk is reduced by lipid-lowering
therapy.2,3 However, despite statin treatment, the risk of
major cardiac events (MACEs) in this population remains
elevated. In addition to traditional cardiovascular (CV)
risk factors, numerous modifiable, and non-modifiable risk
factors have been proposed to contribute to the excessive
CV risk in renal transplant recipients,4,5 and to the risk of
allograft failure.6 One potential risk factor is asymmetric
dimethylarginine (ADMA), an established risk factor for CV
events and all-cause mortality in other populations,7 which
has not been investigated in transplant recipients.
Asymmetric dimethylarginine has also been shown in
patients with chronic kidney disease (CKD) to be an
important risk factor for progression to end-stage renal
disease and all-cause mortality.8
Asymmetric dimethylarginine is an endogenous competitive
inhibitor of nitric oxide synthase and reduces nitric oxide (NO)
generation,9,10 thus inhibiting the beneficial effect of NO
on vasodilatation, arterial stiffness, and endothelial function.11,12
ADMA levels are inversely related to glomerular filtration
rate (GFR) in patients with mild-to-moderate CKD,8,13 and
elevated levels have been associated with CV events and death
in patients receiving hemodialysis.14,15 Thus, ADMA may be
a predictor for renal graft loss, CVevents and all-cause mortality
in patients with different stages of CKD. The contribution of
ADMA for such events in renal transplant recipients is
unknown.
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RESULTS
Baseline characteristics
Basic patients and demographic data in Assessment of Lescol
in Renal Transplantation (ALERT) and the extension ALERT
have been published previously.2,16 Participants in the ALERT
were renal transplant recipients with stable graft function for
a mean duration of 4.5 years before randomization into the
trail. The treatment arms in the ALERT study were
comparable with regard to baseline demographic and clinical
characteristic. There were no differences in ADMA values
between placebo and fluvastatin arms. In this post hoc
analysis, we separated the patients into ADMA quartiles
according to ADMA levels. Estimated glomerular filtration
(ml/min per 1.73m2) was calculated by using the formula
from the Modification of Diet in Renal Disease study.17 The
demographic data are summarized in Table 1. Patients in the
different ADMA quartiles are comparable with regard to age,
blood pressure, lipid levels, body mass index, and serum
calcium and phosphate values. There was a tendency to
increased serum creatinine and decreased estimated GFR
with higher ADMA levels, although ADMA was only weakly
but significantly correlated with serum creatinine (r¼ 0.218,
P¼ 0.000) and as expected inversely correlated with esti-
mated GFR (r¼0.193, P¼ 0.000). Hypertension and use of
antihypertensive drugs was also more common in patients
with higher ADMA levels.
Outcomes
Incident rates for renal, cardiac, cerebrovascular (CBV)
events and for all cause of death in each quartile of ADMA
are summarized in Table 2. Differences between second and
fourth ADMA quartiles versus first quartile were tested
using log-rank test. P-values are given versus first quartile.
Kaplan–Meier curves for survivors in each quartile of ADMA
are shown in Figure 1. Figure 2 shows relative risk for study
outcomes within the asymmetric dimethylarginine (ADMA)
quartiles compared with the first quartile.
Renal end points. The number of graft failure or doubling of
serum creatinine increased in higher ADMA quartiles,
and was highly significant when the third and fourth quartile
was compared with the first quartile. The number of graft failure
and doubling of serum creatinine almost doubled (79 (16.6%) to
137 (29.8%), Po0.001) from the first to the fourth quartile.
Cardiac end points. The number of MACE and cardiac
death or non-fatal myocardial infarction increased in higher
ADMA quartiles. These differences were statistically signifi-
cant between the first and the fourth quartile.
Cerebrovascular events. Rate of CBVevents increased with
increasing ADMA quartiles and the number of CBV events
were more than doubled (3–4 to 11.0%) from the first to the
fourth quartile.
All-cause mortality
Number of all cause of death increased also by ADMA quartiles
and the number of events was almost doubled (13.9 to 26.8%)
in the fourth quartile compared with the first quartile.
Risk factor analysis
The results from the Cox risk factor analyses are summarized
in Table 3. The hazard ratios (HR) with 95% confidence
intervals (95% CI) and corresponding P-values are shown
for all study outcomes. The univariate model included
continuous ADMA values and study outcomes as dependent
variable. The multivariate model was adjusted for potentially
important baseline covariates such as age, gender, systolic
blood pressure, previous CHD, diabetes mellitus, low-density
lipoprotein cholesterol, smoking, and estimated GFR.
In both univariate and multivariate analysis, ADMA
is associated with all study end points. ADMA is an
independent predictor of GFDSC (graft failure and doubling
of serum creatinine): HR 2.78 (95% CI: 1.22–5.82, P¼ 0.009),
MACE: HR 2.61 (95% CI: 1.03–6.61, P¼ 0.042), cardiac
death or non-fatal myocardial infarction: HR 4.90 (95% CI:
1.70–14.10, P¼ 0.003), CBV events: HR 7.63 (95% CI:
2.52–23.13, Po0.001), and all-cause death: HR 4.87
(95% CI: 2.12–11.18, Po0.000).
DISCUSSION
This study is the first to report that plasma levels of ADMA
are associated with increased incidence of MACE, cardiac
death or non-fatal myocardial infarction, CBV events, all-
cause mortality, and deterioration of graft function in renal
transplant recipients. Our findings in this population mirror
previous reports in patient with non-transplanted patients
with or without CKD.18
Epidemiological studies have suggested association
between ADMA and hypertension,19 hypercholesterolemia,20
diabetes mellitus,21 and increased CV risk in CKD.7,9,22,23
Impaired endothelial function is thought to primarily
reflect decreased bioavailability of NO, and an endothelium-
derived vasodilator with anti-atherosclerotic properties.24
In renal transplant recipients, endothelial dysfunction is
well documented, and leads to functional and structural
changes that influence arterial stiffness.25,26 Arterial stiffness,
assessed by pulse wave velocity, is present in renal transplant
recipients, and is enhanced by the use of calcineurin
inhibitors.27,28 Owing to the pre-existing endothelial dysfunc-
tion, renal transplant recipients are at high risk for deleterious
effect of inhibitors of NO, such as ADMA. There is no
established therapy for elevated ADMA, although rosiglita-
zone, amlodipine, and valsartan decrease ADMA level.28,29
Renal transplant recipients have numerous traditional and
non-traditional risk factors for CV events, and although
dyslipidemia-dependent CV events, such as myocardial
infarction,2 are reduced by lipid-lowering therapy, there is a
considerable residual risk for cardiac mortality and morbidity
in these patients.
Although the procedure of renal transplantation may
decrease the raised level associated with hemodialysis, ADMA
is still increased in renal transplant recipients compared with
healthy controls.30 A raised level of ADMA in our study was
associated with a higher incidence of CVevents. In the highest
quartile of ADMA, the incidence was approximately doubled
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Table 1 | Patients’ demographic data in relation to ADMA quartiles in the extension ALERT
ADMA ADMA ADMA ADMA
1. Q 2. Q 3. Q 4. Q
p0.69 0.70–0.77 0.78–0.85 X0.86
N=476 N=462 N=450 N=459
Patients’ demographics (N=1847) Mean (s.d.) Mean (s.d.) Mean (s.d.) Mean (s.d.)
Age at baseline (years) 47.3 (10.5) 49.8 (11.1) 50.3 (10.9) 51.5 (10.8)
Systolic BP (mmHg) 142.9 (18.3) 143.8 (18.8) 144.9 (19.4) 146.1 (18.7)
Diastolic BP (mmHg) 85.8 (9.2) 85.7 (9.65) 85.5 (10.1) 85.5 (10.2)
Total cholesterol (mmol/l) 6.5 (1.2) 6.6 (1.1) 6.5 (1.1) 6.4 (1.1)
HDL cholesterol (mmol/l) 1.4 (0.4) 1.3 (0.4) 1.3 (0.5) 1.3 (0.4)
LDL cholesterol (mmol/l) 4.1 (1.0) 4.3 (1.0) 4.2 (1.0) 4.1 (1.0)
Triglycerides (mmol/l) 2.2 (1.2) 2.2 (1.1) 2.2 (1.2) 2.3 (1.2)
Apolipoprotein B (mg/dl) 116.8 (25.5) 116.3 (24.6) 115.3 (27.6) 116.3 (24.7)
Body mass index (kg/m2) 25.5 (4.3) 25.0 (4.2) 25.7 (4.5) 25.9 (4.7)
Serum creatinine (mmol/l) 133.9 (46.7) 135.7 (41.7) 145.6 (53.9) 163.0 (60.8)
Estimated GFR 52.5 (17.2) 50.5 (14.3) 48.6 (16.0) 44.1 (15.9)
hs-CRP (mg/l) 3.8 (7.0) 3.2 (5.4) 3.7 (6.7) 4.6 (7.7)
Calcium (mmol/l) 2.4 (0.1) 2.4 (0.2) 2.4 (0.2) 2.4 (0.2)
Phosphate (mg/dl) 3.5 (0.6) 3.6 (0.7) 3.5 (0.8) 3.7 (0.8)
ADMA mmol/l 0.64 (0.04) 0.73 (0.02) 0.81 (0.02) 0.95 (0.10)
Transplant characteristics
Time on dialysis (month) 22.0 (37.0) 25 (39.1) 31.2 (47.4) 33.9 (46.0)
Age at last Tx 41.8 (10.9) 44.7 (11.4) 45.4 (11.3) 46.5 (11.2)
Donor age (years) 38.2 (15.4) 40.9 (15.0) 41.7 (15.2) 43.8 (15.2)
Total time on RRT (years) 87.2 (56.1) 86.1 (56.0) 90.0 (60.1) 93.0 (59.1)
Living-donor Tx N (%) 134 (28.2) 102 (22.2) 97 (21.6) 84 (18.3)
Cold ischemia time (h) 19.9 (7.2) 19.6 (7.7) 19.4 (7.5) 19.9 (7.8)
Cardiovascular risk factors N (%) N (%) N (%) N (%)
Diabetes mellitus 96 (20.2) 83 (18.0) 86 (19.2) 83 (18.1)
Hypertension 331 (69.5) 336 (73.0) 343 (76.4) 361 (78.6)
Left-ventricular hypertrophy 48 (10.1) 61 (13.3) 76 (16.9) 89 (19.4)
Chronic heart disease 41 (8.6) 36 (7.8) 41 (9.1) 55 (12.0)
Smoking: previous 180 (37.8) 156 (33.9) 156 (34.7) 158 (34.4)
Smoking: current 64 (13.4) 88 (19.1) 90 (20.0) 105 (22.9)
Primary renal disease
Glomerulonephritis 186 (39.1) 163 (35.4) 172 (38.3) 155 (33.8)
PCKD 62 (13.0) 74 (16.1) 64 (14.3) 85 (18.5)
Diabetic nephropathy 73 (15.3) 60 (13.0) 51 (11.4) 56 (12.2)
Pyelo-interstitial nephritis 56 (11.8) 59 (12.8) 63 (14.0) 55 (12.0)
Hypertension 20 (4.2) 30 (6.5) 19 (4.2) 19 (4.1)
Vasculitis 2 (0.4) 6 (1.3) 6 (1.3) 4 (0.9)
SLE 10 (2.1) 8 (1.7) 5 (1.1) 7 (1.5)
Other case 62 (13.0) 47 (10.2) 52 (11.6) 71 (15.5)
Unknown 22 (4.6) 24 (5.2) 29 (6.5) 23 (5.0)
Concomitant medication
b-Blockers 267 (56.1) 281 (61.1) 282 (62.8) 316 (68.8)
Calcium antagonists 329 (69.1) 324 (70.4) 321 (71.5) 323 (70.4)
ACE inhibitors or AT1-blockers 238 (50.0) 224 (48.7) 220 (49.0) 233 (50.8)
Diuretics 213 (44.7) 245 (53.3) 260 (57.9) 315 (68.6)
a-Blockers 70 (14.7) 69 (15.0) 77 (17.1) 100 (21.8)
Nitrate 34 (7.1) 36 (7.8) 37 (8.2) 47 (10.2)
ASA 148 (31.1) 163 (35.4) 168 (37.4) 175 (38.1)
Cumarine/Warfarin 31 (6.5) 42 (9.1) 36 (8.0) 51 (11.1)
Active D-vitamin 56 (11.8) 57 (12.4) 71 (15.8) 118 (25.7)
Immunosuppressants
Prednisolone 368 (77.3) 385 (83.7) 382 (85.1) 377 (82.1)
Cyclosporine A 467 (98.1) 451 (98.0) 442 (98.4) 446 (97.2)
Azathioprine 333 (70.0) 323 (70.2) 284 (63.3) 269 (58.6)
Mycophenolate mofetil 55 (11.6) 76 (16.5) 65 (14.5) 81 (17.6)
ACE, angiotensin-converting enzyme; ADMA, asymmetric dimethylarginine; ALERT, Assessment of Lescol in Renal Transplantation; ASA, acetyl salicylic acid; AT1, angiotensin II
receptor blocker; BP, blood pressure; GFR, glomerular filtration rate; HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; LDL, low-
density lipoprotein; PCKD, polycystic kidney disease; PTH, parathyroid hormone; Q, quartile; RRT, renal replacement therapy; SLE, systemic lupus erythematosus; TX, renal
transplantation.
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compared with that in the lowest quartile. In heart transplant
patients, elevated ADMA has been associated with coronary
intimal hyperplasia; treatment with sirolimus rather than
mycophenolate resulted in a significant decrease in ADMA
levels and reduced risk of cardiac allograft vasculopathy.31
The experience from the heart study and our study in renal
transplant recipients strongly favor an association between
ADMA levels and cardiac markers and cardiac end points.
Renal transplant recipients also have an increased risk for
a CBV disease and, although the risk factors for ischemic
versus hemorrhagic stroke may vary, stroke occurrence is
several times higher than the background population.32
A somewhat surprising finding in our study was that ADMA
was very strongly related to the occurrence of CBV events in
this population. In healthy individuals, suppressor doses of
ADMA increases arterial stiffness and decreases cerebral
blood flow, and ADMA thus may be involved in the
pathogenesis of CBV disease.33 In several papers, stroke is
part of a composite CV end point, but is not reported
separately.18,34 An association of stroke incidence and ADMA
is therefore difficult to assess. To our knowledge, our study is
the first to show a strong association between ADMA levels
and stroke events.
In patients with CKD, the levels of ADMA are increased
compared with those in patients with normal renal function.
Elevated ADMA level in the circulation are a combined result
of impaired kidney function and a reduced activity of
the enzymatic catabolism of ADMA by dimethylarginine
dimethylaminohydrolase.35 Plasma level of ADMA is elevated
in all types of patients with impaired renal function, with
maximal (sevenfold) elevation in patient with end-stage renal
disease treated by hemodialysis. About 60% of ADMA is
removed during a hemodialysis session.9,36,37
Numerous experimental study suggests that reduced NO
activity is involved in progressive kidney damage in patients
with CKD.38–42
After successful renal transplantation, ADMA is decreased
and is associated with an improvement in endothelial
function, albeit without any effect on graft function.30 In
non-transplant patients with CKD Ravani et al.8 showed
Table 2 | Event rates for outcomes by ADMA quartiles
ADMA 1.Q ADMA 2.Q ADMA 3.Q ADMA 4.Q
p69 0.70–0.77 0.78–0.85 0.86+
End points N=476 N=460 N=449 N=459
GFDSC N (%) 79 (16.6) 87 (18.9) 96 (21.4) 137 (29.8)
P-value — 0.396 0.047 o0.001
MACE N (%) 62 (13.0) 62 (13.5) 70 (15.6) 87 (18.9)
P-value — 0.813 0.216 0.005
CDNFMI N (%) 42 (8.8) 43 (9.3) 51 (11.4) 71 (15.5)
P-Value — 0.760 0.172 0.001
CBV events N (%) 22 (4.60) 45 (9.8) 55 (12.3) 52 (11.3)
P-value — 0.003 o0.001 o0.001
All causes of death N (%) 63 (13.9) 71 (15.4) 86 (19.2) 123 (26.9)
P-value — 0.549 0.038 o0.001
ADMA, asymmetric dimethylarginine; CBV, cerebrovascular; CDNFMI, cardiac death or
non-fatal myocardial infarction; GFDSC, graft failure or doubling of serum creatinine;
MACE, major adverse cardiovascular events; Q, quartile.
Data expressed as number of patients in quartile/number of event (%). Significance
versus first quartile.
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Figure 1 |Kaplan-Meier curves for study end points by
asymmetric dimethylarginine (ADMA) quartiles. (a) MACE,
major cardiac events. (b) GFDSC, graft failure or doubling of serum
creatinine. (c) CBV events, cerebrovascular events. (d) All-cause
mortality. Numbers 1–4 denote ADMA quartiles 1–4. The x axis
indicates follow-up time in years; the y axis indicates cumulative
survival by ADMA quartile.
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Figure 2 |Relative risk for study outcomes within the
asymmetric dimethylarginine (ADMA) quartiles compared
with the first quartile. x axis, ADMA quartiles 1–4; y axis, relative
risk. CBV, cerebrovascular; CDNFMI, cardiac death or non-fatal
myocardial infarction; GFDSC, graft failure or doubling of serum
creatinine; MACE, major cardiac event. *Denotes significant
difference in relative risk compared with ADMA in first quartile,
P-value o0.05. Q, quartile.
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that ADMA was a strong and independent risk marker for
progression to end-stage renal disease. There are numerous
reports that ADMA is associated with progressive renal
dysfunction and also with progression to end-stage renal
disease, but no publication has assessed ADMA as a potential
risk factor for graft failure. In our study, ADMA was, after
adjustments for serum creatinine and proteinuria, inde-
pendently associated with long-term deterioration of graft
function in renal transplant patients.
Potential limitations of our study merit considerations.
Although we have shown a strong association between
ADMA levels and clinical outcomes, the data do not imply
a causal relationship. Erythropoietin use was not registered
in our database. Erythropoietin might influence endothelial
cell production of ADMA,43 however, that is not likely to
be a major concern in this stable cohort of renal transplant
recipients with a rather well-preserved renal function after
transplantation. The patients in fourth quartile had more
comorbid conditions compared with patients in the first
quartile, and this was reflected in increased ADMA concen-
trations. The strength of the study is the randomized control
design, the long follow-up time and the independent
adjudication of all clinical end points.
In conclusion, this is the first study to report that ADMA
levels are associated with deterioration of graft function,
cardiac death and non-fatal myocardial infarction, CBV
events, and mortality in renal transplant recipients. Increased
levels of ADMA might explain some of the excess CV
morbidity and mortality, and should be target for future
investigations in this population. ADMA levels may be used
in risk stratification and identification of renal transplant
recipients at high risk of CV disease and graft loss, and may
be modifiable by treatment. Clinical trials to assess the
potential of therapeutic reductions in ADMA level on CV
and renal end points will be eagerly awaited in this
population, as ADMA might be associated with adverse
outcomes.
MATERIALS AND METHODS
Study design
The ALERT study design and baseline data have been described
previously.16 Briefly, ALERT was a randomized, double-blind,
placebo-controlled study of the effect of fluvastatin, 40–80mg
daily, on cardiac and renal outcomes in 2102 renal transplant
recipients over a follow-up period of 5–6 years. Eligible patients
were men and women aged 30–75 years, who had received a
renal transplant more than 6 months earlier and had a serum
total cholesterol concentration between 4.0 and 9.0mmol/l
(155–348mg/dl). Patients were excluded if they were on statin
therapy, had familial hypercholesterolemia, or had experienced
an acute rejection episode in the 3 months before randomiza-
tion. In addition, patients with a predicted life expectancy
of less than 1 year were excluded. Of 1787 patients who
completed ALERT, 1652 (92%) were offered open-label
fluvastatin 80mg/dag in a 2-year extension to the original
study. Mean total follow-up time in the extension study
was 6.7 years.3 The study adhered to the International
Conference on Harmonization guidelines for Good Clinical
Practice and is in accordance with the Declaration of Helsinki
Principles. All participants provided written informed consent,
and the ethics committee at each participating center approved
the trial.
Outcome definitions
Renal end point was the time to GFDSC. Cardiac end point
was MACE and was defined as cardiac death, non-fatal
myocardial infarction, or coronary intervention procedure.
CBV event was defined as any CBV event, including fatal
and non-fatal stroke. All end points were validated by an
independent clinical end point committee blinded to study
drug allocation.2,16
Laboratory
Inclusion laboratory values of the ALERT trial are reported
previously.16 ADMA levels were measured in blood samples
obtained at inclusion in 1847 patients.16 ADMA was
measured in frozen serum (801C) with reversed-phased
HPLC (high-performance liquid chromatography).44
Statistical analysis
In the initial analysis, the treatment and placebo arms were
analyzed separately for clinical events. As the two arms
showed no significant heterogeneity in relationships between
ADMA as a risk factor and event outcome, subsequent
Table 3 | Hazard ratios for ADMA by univariate and multivariate Cox proportional hazard models in 1847 renal transplant
recipients
Extension ALERT study (placebo+fluvastatin)
Study end points HR (95% CI) univariate P-value HR (95 % CI) multivariate P-value
GFDSC 10.50 (5.34–20.66) o0.001 2.78 (1.22–5.82) 0.009
MACE 4.41 (1.92–10.14) o0.001 2.61 (1.03–6.61) 0.042
CDNFMI 7.32 (2.88–18.65) o0.001 4.90 (1.70–14.10) 0.003
Cerebrovascular events 10.32 (3.79–28.07) o0.001 7.63 (2.52–23.13) o0.000
All-cause death 9.25 (4.50–19.00) o0.001 4.87 (2.12–11.18) o0.000
ADMA, asymmetric dimethylarginine; CBV, cerebrovascular events; CDNFMI, cardiac death or non-fatal myocardial infarction; GFDSC, graft failure or doubling of serum
creatinine; MACE, major adverse cardiovascular events.
Hazard ratios were adjusted for clinically important covariates as age, gender, systolic blood pressure, previous CHD, diabetes mellitus, LDL-cholesterol, smoking, and serum
creatinine in the multivariate Cox model.
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analysis was performed on the pooled patient population.
SPSS version 16.0 (2008 SPSS, Chicago, USA) was used for
statistical analysis. For normally distributed variables, mean
and s.d. are presented. Demographic and clinical baseline
characteristics were compared using independent samples
t-test and w2-test for continuous and categorical variables,
respectively. A Cox proportional hazard model was used to
analyze the relationship between risk factors and time to
event for all end points. All covariates were carefully
examined and fulfilled the assumptions of proportionality
of HR in the Cox hazard models. Univariate and multivariate
analysis were then carried out to determine the association of
ADMA with cardiac and renal events (GFDSC, major adverse
cardiac events (MACE—myocardial infarction, cardiac death,
and coronary interventions), cardiac death and non-fatal
myocardial infarction, all-cause mortality, and CBV events).
Corresponding HR for group comparisons were calculated
with 95% confidence limits.
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